Maia Biotechnology
Biotechnology, 444 W Lk St, Chicago, Illinois, 60606, United States, 1-10 Employees
Phone Number: 31********
Who is MAIA BIOTECHNOLOGY
MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended t...
Read More
- Headquarters: 444 W Lk St, Chicago, Illinois, 60606, United States
- Date Founded: 2018
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
- CEO: Vlad Vitoc
Industry: Biotechnology
SIC Code: 2836 | NAICS Code: 541714 | Show More
Does something look wrong? Fix it. | View contact records from MAIA BIOTECHNOLOGY
MAIA Biotechnology Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MAIA Biotechnology
Answer: MAIA Biotechnology's headquarters are located at 444 W Lk St, Chicago, Illinois, 60606, United States
Answer: MAIA Biotechnology's phone number is 31********
Answer: MAIA Biotechnology's official website is https://maiabiotech.com
Answer: MAIA Biotechnology's revenue is $1 Million to $5 Million
Answer: MAIA Biotechnology's SIC: 2836
Answer: MAIA Biotechnology's NAICS: 541714
Answer: MAIA Biotechnology has 1-10 employees
Answer: MAIA Biotechnology is in Biotechnology
Answer: MAIA Biotechnology contact info: Phone number: 31******** Website: https://maiabiotech.com
Answer: MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIAs business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIAs business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month